A review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.
Brussels, Belgium-based UCB entered into a global licensing deal with Roche and Genentech to develop and commercialize UCB0107 in Alzheimer’s disease.
In a review of recently published scientific studies, researchers with Queen Mary University of London discovered a gene that naturally suppresses the signs of Alzheimer’s disease in human brain cells.
AC Immune initiated the second highest dosing group in the company’s Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease, based on encouraging interim data from the initial dosing cohort.
The U.S. Food and Drug Administration approved drugmaker Eli Lilly and Co.’s radioactive compound to detect tau, an important characteristic of Alzheimer’s disease.
75 top Alzheimer’s and dementia experts collaborated on a 10-year strategic plan for researchers, policymakers and caregivers May 21, 2020 –– A new report released today by AARP and the […]
Data-focused CRO MMS Holdings Inc. announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. resulted in gaining U.S. Food and Drug Administration approval of an Investigational New Drug application for the GV-971 international multi-center Phase III clinical study in the treatment of patients with Alzheimer’s disease.
Axsome Therapeutics announced that the company’s AXS-05 met the primary endpoint in the ADVANCE-1 Phase II/III clinical trial for agitation in patients with Alzheimer’s disease.
Biogen presented first-quarter earnings for 2020, and one of the announcements was that although the company had begun to submit parts of a Biological License Application for the Alzheimer’s drug aducanumab, the BLA was not expected to be completed until the third quarter of 2020.
For some time, there has been speculation that glucose metabolism was associated with Alzheimer’s disease, with some researchers going so far as to call Alzheimer’s diabetes type 3. Researchers with the National Institutes of Health’s National Institute on Aging conducted the largest study so far on proteins related to Alzheimer’s and identified proteins and biological processes that regulate glucose metabolism that are associated with Alzheimer’s. The study was published in the journal Nature Medicine.
